Nasdaq

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

DURHAM, N.C., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
Nasdaq

Claritev and Lantern Form Strategic Partnership to Enhance Surgical Cost Transparency and Positively Impact Care Quality and Cost Savings

The partnership integrates Claritev’s innovative solutions with Lantern’s Specialty Care Platform to optimize healthcare costs for Lantern’s footprint. MCLEAN, Va.--(BUSINESS WIRE)-- Claritev ...
Fox 5 San Diego

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

- Humacyte plans to advance CTEV into first-in-human study in CABG - DURHAM, N.C., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company ...